[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetes-mellitus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetes-mellitus":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,253,0,25,[9,52,75,103,129,167,188,215,245,280,303,333,361,385,416,444,471,506,525,547,573,595,613,636,669],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100652708","effects-of-otago-exercise-versus-multisensory-integration-training-on-balance-and-gait-in-elderly-with-diabetes-100652708",false,"NCT07776535","Effects Of Otago Exercise Versus Multisensory Integration Training On Balance And Gait In Elderly With Diabetes","Balance - DM","Inclusion Criteria:\n\n1. Ninety elderly Patients of both genders.\n2. Their age will range from 65 to 75th.\n3. They will be diagnosed with type 2 diabetes for 5 years or more.\n4. Patients with mild \\& moderate neuropathy will be included. (Based on the Toronto scale: -mild (6-8); moderate (9-11)\n5. Berg balance between (21 to \\\u003C50) patients with mild \\&moderate risk of fall .\n6. Time up \\& go dual task: patient takes longer than 10 sec.\n7. HBA1C for these patients was ≥ 6.5% .\n8. BMI will range from (18: 29,9 kg\u002Fm2).\n9. Able to walk independently, with or without assistive devices.\n\nExclusion Criteria:\n\n1. Any musculoskeletal disorder affecting the lower limb (fracture of the lower limb, tumors, any infection, ligament injuries, foot injuries).\n2. Any other neurological disorder influences gait such as (stroke, Parkinson's disease, cerebellar dysfunction, ataxia, vestibular disorders)\n3. Any other cardiovascular disease (arrhythmia, cardiac pacemakers).\n4. Unstable proliferative retinopathy and visual impairments without correction.\n5. Non-diabetic neuropathy (inflammatory, autoimmune disease, infections, tumors, vitamin B12 deficiency, hypothyroidism, alcoholism, injury or pressure on the nerve).\n6. The use of medications significantly impacting postural control (e.g., sedatives).\n7. Vestibular system and Cognitive disorders.\n8. Uncontrolled hypertension.\n9. Common peroneal nerve injury.\n10. Orthostatic hypotension.","ALL","65 Years","75 Years",{"count":21,"type":22},90,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to compare the effect of the Otago exercise and Multisensory integration training on balance and gait in the elderly with type 2 diabetes mellitus.\n\nThe main question it aims to answer is:\n\n• Is there a significant difference between the effect of Otago exercise and Multisensory integration training on balance and gait in the elderly with type 2 diabetes mellitus? Researchers will compare Otago exercise to Multisensory integration training to know which one has the greatest benefit on balance \\&gait in the elderly with type2 diabetes.\n\nParticipants will be divided into 3 groups; each group takes a certain training program for 8 weeks:\n\n* First group: Otago exercise group plus conventional treatment for neuropathy.\n* Second group: Multisensory integration training group plus conventional treatment for neuropathy.\n* Third group: control group takes only conventional treatment for neuropathy.",[28,29,30],"Balance","Gait","Diabetes Mellitus",[32,33,34,35,36,37,38],"otago exercise","multisensory integration","balance disorder","gait proplem","diabetes","elderly","older adults","NOT_YET_RECRUITING","2026-08-17",{"date":42,"type":43},"2026-08-20","ACTUAL",{"date":45,"type":22},"2026-10",{"date":47,"type":22},"2027-11",{"name":49,"class":50},"Cairo University","OTHER",1,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":51},"100471208","impact-of-removable-cast-walker-design-on-usability-for-patients-with-diabetic-foot-ulcers-100471208","NCT05415878","Impact of Removable Cast Walker Design on Usability for Patients With Diabetic Foot Ulcers","Improving Diabetic Foot Ulcer Offloading: A Pilot Study on the Impact of Removable Cast Walker Design Factors on Usability","Inclusion Criteria:\n\n* presence of a full thickness plantar (forefoot) diabetic foot ulcer ≥1cm2 that is being treated on an outpatient basis with a University of Texas wound classification of 1A-C or 2 A-C;\n* self-reported ability to walk for at least two continuous minutes at a self-selected speed\n* confirmation of the presence of diabetic peripheral neuropathy as identified by failure to detect a 10 gram Semmes Weinstein Monofilament on either foot at one of four sites tested (1st, 3rd, 5th metatarsal heads, and plantar surface of hallux) OR a vibration perception threshold value of 25 or more at either hallux.\n\nExclusion Criteria:\n\n* lower extremity amputation more proximal than transmetatarsal on either limb\n* chronic kidney disease stage 4 or higher (i.e., currently undergoing dialysis or eGFR\\\u003C30 within last 60 days)\n* active Charcot neuroarthropathy\n* severe peripheral arterial disease (non-palpable pulse at posterior tibia and dorsalis pedis arteries, and an ankle brachial index\\\u003C0.7)\n* gait\u002Fbalance disturbance not attributable to diabetes (e.g. neuromuscular disease or cerebrovascular vascular accident)\n* current or previous (within past year) use of an ankle-high RCW or of a contralateral lift to offset an RCW-induced LLD","18 Years",{"count":61,"type":22},40,[25],"Within their lifetime, over 30% of people living with diabetes will develop a diabetic foot ulcer (DFU), many of which will never heal and may require amputation. Removable cast walkers (RCWs) are commonly prescribed to offload (treat) DFUs. While RCWs are prescribed to be worn during all weight bearing activities, adherence to this prescription is low. This is a serious concern given that low adherence predicts poor DFU healing. This study will provide pilot\u002Ffeasibility data to inform a larger clinical trial to evaluate the impact of existing RCW designs on adherence and DFU healing. We will also quantify the effect of RCW form on biomechanical and self-reported measures related to usability. Our working hypothesis is that healing outcomes with a given RCW will be predicted by biomechanical and self-reported measures of RCW usability, with the predictive relationship partly explained by the effect of these measures on adherence.",[30,65],"Foot Ulcer","RECRUITING",{"date":68,"type":43},"2026-08-19",{"date":70,"type":43},"2023-08-02",{"date":72,"type":22},"2027-05-30",{"name":74,"class":50},"Rosalind Franklin University of Medicine and Science",{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":59,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":51},"100625641","integrated-oral-care-intervention-for-xerostomia-in-diabetes-patients-100625641","NCT07425275","Integrated Oral Care Intervention for Xerostomia in Diabetes Patients","The Impact of Integrated Oral Care Intervention Provided by Endocrinologists on Oral Health and Well-being in Diabetes Patients","IOCID","Inclusion Criteria:\n\n* Presence of a single stone in the renal pelvis.\n* Age less than 18 years.\n* No congenital or acquired urinary tract abnormalities.\n* No pre-existing chest diseases (e.g., chronic lung disease, pleural effusion).\n\nExclusion Criteria:\n\n* Patients with multiple kidney stones.\n* Calyceal stones (stones located specifically in a calyx).\n* Pelviureteric junction obstruction (PUJO).\n* Pelvic kidney (renal ectopia).",{"count":84,"type":22},80,[25],"Diabetes patients commonly experience dry mouth also known as xerostomia which can affect eating speaking oral health and overall quality of life. This study evaluates whether simple oral care actions delivered by endocrinologists during routine diabetes clinic visits can improve dry mouth symptoms and oral health related quality of life. Endocrinologists will be trained to screen for dry mouth provide brief counseling prescribe saliva substitutes and refer patients to dental services when needed. Adult patients with diabetes and symptoms of dry mouth will be followed before and after the intervention to assess changes in xerostomia severity and oral health outcomes. The study will also explore barriers and facilitators to integrating oral health care into routine diabetes management in Pakistan.",[30,88],"Diabetic Neuropathies",[90,91,92,93],"Diabetes mellitus","Oral health quality of life","Non communicable diseases","Integrated oral care","2026-08-16",{"date":96,"type":43},"2026-08-18",{"date":98,"type":43},"2026-08-01",{"date":100,"type":22},"2027-01-30",{"name":102,"class":50},"Khyber Medical University Peshawar",{"id":104,"slug":105,"hasResults":12,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":110,"sex":17,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":4,"leadSponsor":126,"locationsCount":51},"100054896","genetic-studies-of-insulin-and-diabetes-100054896","NCT00001987","Genetic Studies of Insulin and Diabetes","Natural History of Disorders of Insulin Resistance","* INCLUSION CRITERIA:\n\nThree categories of subjects will be included in this study:\n\n* Patients with evidence for insulin resistance or a disorder associated with severe insulin resistance, including:\n\n  * Patients with various syndromes of lipodystrophy\n  * Patients with known or suspected mutations on the insulin receptor gene\n  * Patients with known or suspected autoantibodies to the insulin receptor\n  * Patients with other severe forms of insulin resistance\n* Family members of patients, above\n* Healthy control subjects without insulin resistance\n\nInclusion criteria for each group of subjects are given below:\n\n* Patients with evidence for severe insulin resistance or a disorder associated with severe insulin resistance must meet all of the following criteria:\n\n  * Suspected severe insulin resistance, or a disorder associated with severe insulin resistance, as evidenced by one or more of the following:\n  * Hyperinsulinemia (i.e. fasting insulin \\>30microU\u002FmL)\n  * High insulin requirement (\\> 2 units per kg per day or \\> 200 units total per day)\n  * Phenotypic features suggesting a defect in glucose\u002Flipid metabolism:\n\n    * Acanthosis nigricans\n    * Lipodystrophy\u002Fabnormal fat distribution\n    * Xanthomata\n    * Fatty liver\n  * Known or suspected mutations of the insulin receptor gene\n  * Known or suspected autoantibodies to the insulin receptor\n  * Age \\>= 6 months\n  * Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.\n* Family members of patients, above (either affected or unaffected) must meet all of the following criteria:\n\n  * Biological relatives of patients in category (1) in whom a genetic cause of insulin resistance is known or suspected.\n  * Age \\>= 6 months\n  * Ability of subject (and\u002For legal guardian, for minor subjects) to understand and the willingness to sign a written informed assent\u002Fconsent document.\n* Healthy control subjects Cohort 1 must meet all of the following criteria.\n\n  * Ability of subject (and\u002For legal guardian, for minor subjects) to understand and the willingness to sign a written informed assent\u002Fconsent document.\n  * In good general health with no known active medical conditions as evidenced by medical history\n  * Age \\>= 12 years\n* Healthy control subjects Cohort 2. Subjects from Cohort 1 may be included in Cohort 2 if they meet the following ADDITIONAL inclusion criteria.\n\n  * Fasting glucose \\\u003C100 mg\u002FdL\n  * HbA1c \\\u003C5.7%\n  * Fasting triglycerides \\\u003C150 mg\u002FdL\n  * Fasting insulin \\\u003C30 mcU\u002FmL\n  * BMI \\\u003C27 kg\u002Fm\\^2 or \\\u003C90th percentile for age\u002Fsex (whichever is lower)\n\nEXCLUSION CRITERIA:\n\n* Patients with evidence for insulin resistance or a disorder associated with severe insulin resistance\n\n  --none\n* Family members of patients, above\n\n  --Pregnant at the time of enrollment\n* Healthy control subjects Cohort 1\n\n  * Current use of prescription or non-prescription medication. Certain exceptions are permitted, including topical medications, vitamins, and hormonal contraceptives. Other medications may be permitted at the discretion of the investigators.\n  * Recent (past 2 months) use of drugs or supplements that alter glucose or lipid metabolism (e.g. niacin, fish oil, red yeast rice)\n  * History of diabetes or abnormal glucose tolerance\n  * Psychiatric or cognitive disorder that will, in the opinion of the investigators, limit the subject's ability to provide informed consent\u002Fassent, or to comply with study procedures\n  * Pregnant or lactating\n* Healthy control subjects Cohort 2. Subjects from Cohort 1 may NOT be included in Cohort 2 if they have any of the following ADDITIONAL exclusion criteria.\n\n  * Abnormal screening labs, including the following:\n\n    * ALT or AST more than 1.5 times the upper limit of normal\n    * Glycosuria\n    * Clinically significant anemia\n    * Low eGFR (\\\u003C60 mL\u002Fmin\u002F1.73m\\^2)\n    * Any other abnormality that, in the opinion of the investigator, will increase risk to the subject from participation, or interfere with interpretation of study data",true,"6 Months","120 Years",{"count":114,"type":22},1200,"OBSERVATIONAL","The study will allow researchers to obtain blood, plasma, DNA, and RNA for genetic studies of insulin. There will be a focus on the causes of insulin resistance and diabetes mellitus. Insulin is a hormone found in the body that controls the level of sugar in the blood. Insulin resistance refers to conditions like diabetes when insulin does not work properly. In this study researchers would like to compare patients with diabetes and other forms of insulin resistance to normal individuals. The study will investigate how insulin attaches to cells.\n\nResearchers will take 4 to 6 ounces (100-150 ml) of blood from adult patients and may request up to 12 ounces (one unit) of blood if necessary. Skin samples may be taken for a biopsy if further genetic testing is necessary. In addition some patients may be asked not to eat for up to 72 hours prior to testing....",[30,118],"Severe Insulin Resistance",[30,118,120,121],"Type B Insulin Resistance","Natural History","2026-08-15",{"date":96,"type":43},{"date":125,"type":43},"1976-02-01",{"name":127,"class":128},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":12,"sex":17,"minAge":59,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":140,"briefSummary":141,"conditions":142,"keywords":147,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":166},"100611282","a-novel-digital-tool-physicians-can-use-to-prescribe-exercise-to-patients-with-cardiovascular-disease-risk-factors-100611282","NCT07238556","A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors","Feasibility and Acceptability of a Novel Algorithm for Physicians to Prescribe Personalized Exercise Prescriptions to Patients With Cardiovascular Disease Risk Factors: Study Protocol for an Exploratory Randomized Controlled Crossover Trial","P3-EX","Physician Inclusion Criteria\n\n1. Practicing medical doctors employed at the study recruitment sites\n2. Do not recommend written exercise programs or plans to their patients, nor refer them to exercise clinics or exercise professionals\n3. Are willing to recruit two of their patients to deliver Prioritize Personalize Prescribe EXercise (P3-EX) and American College of Sports Medicine Physical Activity Vital Sign (ACSM PAVS)\n\nPatient Inclusion Criteria\n\n1. Sedentary: have not performed planned, structured physical activity at moderate intensity for ≥30 minutes on ≥3 days per week in the last 3 months\n2. Adults: ≥18 and ≤64 yrs\n3. ≥1 cardiovascular disease risk factors: Having obesity, hypertension, dyslipidemia, and\u002For diabetes (or prediabetes)\n\n   * Obesity: BMI ≥30 kg\u002Fm2 or WC \\>102 cm (40 in) for men and \\>88 cm (35 in) for women\n   * Hypertension: Systolic BP ≥130 mm Hg and\u002For diastolic BP ≥80 mm Hg, or on antihypertensive medication\n   * Dyslipidemia: LDL-C ≥130 mg\u002FdL (3.37 mmol\u002FL), or HDL-C \\\u003C40 mg\u002FdL (1.04 mmol\u002FL) in men and \\\u003C50 mg\u002FdL (1.3 mmol\u002FL) in women, or non-HDL-C ≥160 mg\u002FdL (4.14 mmol\u002FL), or on lipid-lowering medication, or TC ≥200 mg\u002FdL (5.18 mmol\u002FL)\n   * Diabetes (or prediabetes): FBG ≥100 mg\u002FdL or HbA1c ≥5.7%, or on medication for diabetes\n4. Healthy: Having no signs or symptoms of or have cardiovascular or renal disease, or other diseases or health conditions that significantly limit physical activity engagement\n5. Not pregnant or lactating\n6. Not a cigarette smoker or quit smoking ≥6 months ago\n7. Consume \\\u003C2 alcoholic drinks daily\n8. Able to use a computer or phone with internet access\n9. Fluent in English\n10. Willing to maintain their medication routine and habitual diet and not follow other exercise or nutrition programs.\n\nPatient Exclusion Criteria 4a. Have pain or discomfort in the chest, neck, jaw, or arms; dizziness or syncope; shortness of breath at rest or with mild exertion; unusual fatigue or shortness of breath with usual activities; orthopnea; ankle edema; intermittent claudication; palpitations; or known heart murmur 4b. Stroke or cancer survivors or currently have cancer, chronic obstructive pulmonary disease, musculoskeletal injury, chronic back pain, depression, dementia, or other diseases or health conditions that are deemed to significantly limit physical activity engagement.","64 Years",{"count":139,"type":22},72,[25],"The investigators will conduct a feasibility and pilot efficacy randomized controlled trial to test the usability and user satisfaction of an evidence-based digital health tool the investigators developed for physicians to use to Prioritize Personalize Prescribe EXercise (P3-EX) to patients with cardiovascular disease (CVD) risk factors. The investigators will recruit 24 physicians from two local hospitals in CT, USA. Physicians will recruit two patients each (N=48) having CVD risk factors. Physicians will deliver a P3-EX exercise prescription (ExRx) to one of their patients (n=24) and the American College of Sports Medicine Physical Activity Vital Sign (ACSM-PAVS) ExRx to the other (n=24) in a random sequence crossover design. Physicians and patients will rate the feasibility and acceptability of each method using validated questionnaires. Patients will perform their prescribed ExRx for 12 weeks and complete a self-report exercise diary to monitor exercise adherence with virtual oversight from University of Connecticut (UConn) Graduate Research Assistants. Before and after the exercise intervention, the investigators will measure patient CVD risk factors and physical activity (PA) levels via accelerometry. The primary aim is to evaluate the feasibility and acceptability of P3-EX for physicians to use to prescribe exercise to patients with CVD risk factors, and the secondary aim is to explore the preliminary efficacy of P3-EX to improve patient CVD risk factors, PA levels, and exercise adherence. The investigators hypothesize P3-EX will be feasible for physicians to use to prescribe customized exercise routines for patients with CVD risk factors, and physicians and patients will be satisfied with P3-EX.",[143,144,30,145,146],"Hypertension","Dyslipidemia","Obesity","Cardiovascular Disease",[148,149,150,151,152,153,154,155,156],"Exercise prescription","Exercise Therapy","Physical Activity","Preventive Health Services","Health Behavior","Medical Informatics Applications","Health technology","Precision Medicine","Primary Health Care","2026-08-11",{"date":159,"type":43},"2026-08-12",{"date":161,"type":43},"2026-03-30",{"date":163,"type":22},"2026-12-31",{"name":165,"class":50},"University of Connecticut",3,{"id":168,"slug":169,"hasResults":12,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":12,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":51},"100493387","ai-screening-for-diabetic-retinopathy-100493387","NCT05704491","AI Screening for Diabetic Retinopathy","Accuracy of an AI Model for Diabetic Retinopathy Screening in Real-life","AimdR","Inclusion Criteria:\n\n* Diagnosis of diabetes mellitus\n* Diabetes duration ≥ 5 years\n* Age \\> 18 years old\n* Patient is able to give informed consent\n* Fluent in written and spoken German, or interpreter present\n\nExclusion Criteria:\n\n* History of laser treatment\n* Contraindication to the fundus imaging systems used in the study",{"count":176,"type":22},100,"The increasing prevalence of diabetes mellitus represents a major health problem, especially since around 40% of diabetic patients develop diabetic retinopathy, which severely impairs vision and can lead to blindness. This development could be prevented by annual check-ups and timely referral for treatment. However, there are major differences in the quality of examinations and bottlenecks in examination appointments. A solution to the problem could be the use of artificial intelligence (AI), especially deep learning. Initial studies have shown that deep learning algorithms can be used successfully to detect diabetic retinopathy. However, it remains to be clarified whether the use of AI can achieve a sufficiently high level of accuracy in the detection of retinopathies. Therefore, in the present study, the positive predictive value (PPV), the negative predictive value (NPV), the sensitivity (SEN) and the specificity (SPEZ) of the AI algorithm 'MONA-DR-Model' in the detection of diabetic retinopathy should be measured. In addition, it is to be examined how well the classification into mild and severe retinopathy corresponds and how well this new examination method is accepted by the patients.",[30],"2026-08-06",{"date":181,"type":43},"2026-08-10",{"date":183,"type":43},"2023-01-30",{"date":185,"type":22},"2027-12-31",{"name":187,"class":50},"West German Center of Diabetes and Health",{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":110,"sex":17,"minAge":195,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":51},"100322739","early-tracking-of-childhood-health-determinants-etched-study-100322739","NCT03481829","Early Tracking of Childhood Health Determinants (ETCHED) Study","Early Tracking of Childhood Health Determinants Study","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Pregnant women aged 18 years or older (pregnancy confirmed by urine or serum pregnancy test, or ultrasound examination)\n2. American Indian or Hispanic by self-report\n3. Agree to continue with research study participation (both mother and their offspring), for at least 3 years after delivery.\n\nIn case where a pregnant mother is carrying multiple fetuses (multiple pregnancy), she will be eligible to participate in this study and all her live newborns, as a result of that pregnancy, will be eligible for participation in this study. Mothers will also be eligible to participate with any consecutive pregnancies.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Women who are incarcerated or are unable to consent.\n2. Women whose fetus is not viable or are not planning to continue the pregnancy.","1 Day","99 Years",{"count":198,"type":22},1500,"Background:\n\nChildren s weight has increased sharply in recent years. This may put them at higher risk for health problems. High blood glucose in a pregnant mother and too much weight gain during pregnancy also may have long-term effects on the child s health. Children who become overweight or obese during childhood tend to remain so as adults. Researchers want to study many risk factors during and after pregnancy, and how these affect a child s development. They will also follow the mother s health and well-being after pregnancy.\n\nObjectives:\n\nTo learn how a pregnant mother s environment, lifestyle, and health conditions may affect her child s growth and development from birth until adulthood.\n\nEligibility:\n\nAmerican Indian\u002FAlaska Native (AI\u002FAN) or Hispanic adult pregnant women and their offspring.\n\nDesign:\n\nMothers will have 3 visits during pregnancy.\n\nIn the child s first year, mothers will have 2 visits and their child will have 4.\n\nChildren will have 2 visits in their second year and 1 each year until they turn 18.\n\nMothers will have a visit 2 years after birth and 4-5 years later.\n\nBoth the mother and child s medical records will be reviewed. They will have physical exams and give blood and stool samples.\n\nMothers may give cord blood and placenta samples. They will give breastmilk and urine samples. They will fill out questionnaires.\n\nThey will have an ultrasound. They may get an activity monitor.\n\nMother and child will be followed until the child s 18th birthday.",[30,145,201],"Fatty Liver",[203,145,204,205,206,207,121],"American Indians, Hispanics","Pregnancy","Diabetes","Children","Hispanics",{"date":209,"type":43},"2026-08-07",{"date":211,"type":43},"2022-04-14",{"date":213,"type":22},"2041-12-31",{"name":127,"class":128},{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":223,"targetDuration":225,"studyType":115,"phases":4,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":51},"100650767","domestication-and-implementation-of-the-pen-plus-clinical-model-in-the-zambian-health-system-100650767","NCT07753681","Domestication and Implementation of the PEN-Plus Clinical Model in the Zambian Health System","PEN-Plus Initiation Grant Opportunity: Domestication and Implementation of the PEN-Plus Clinical Model in the Zambian Health System","PEN Plus","Inclusion Criteria:\n\n* Presenting with chronic NCDs\n\nExclusion Criteria:\n\n* Refusing to be followed up prospectively for routine visits",{"count":224,"type":22},2084,"1 Month","Cognizant of the prevalence of complicated non communicable diseases (NCD) and the attendant capacity problems faced by the health workers in primary care settings, we propose to adapt and pilot the Package of Essential Non-communicable Diseases (PEN) Plus intervention using the Interactive Systems Framework (ISF) and then implement and monitor the impact. The ISF framework proposes and organizes several implementation strategies to achieve Evidence Based Implementation (EBI) adaptation. We will apply these strategies at 2 first level hospitals (Peri-Urban and Rural) to ensure local adaptation and work towards scaling up of the WHO-PEN Plus in the rest of Zambia. This process will be inclusive, involving a Stakeholder Consultation Group that shall include the Zambian Non-Communicable diseases and injuries (NCDI) Poverty Commission and shall report bi-annually to a Project Advisory Board (PAB) chaired by the Permanent Secretary of the Ministry of Health.",[228,229,143,30,230,231,232,233,234,235,236],"Cardiac Diseases","Sickle Cell Disease","Heart Failure","Congenital Heart Disease","Rheumatic Heart Disease","Epilepsy","Cancer","Mental Health Disorders","Kidney Disease","2026-08-04",{"date":209,"type":43},{"date":240,"type":43},"2022-08-08",{"date":242,"type":22},"2027-09-30",{"name":244,"class":50},"Centre for Infectious Disease Research in Zambia",{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":12,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":23,"phases":254,"briefSummary":255,"conditions":256,"keywords":262,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":4},"100650187","the-bright-study-device-name-halo-system-100650187","NCT07745998","The BRIGHT Study (Device Name: HALO System)","The BRIGHT Study, an Open Label, Single-arm, Interventional, Multicenter, Prospective Study of the Diagnostic Feasibility of the HALO System, Designed to Evaluate the Safety and Performance of the HALO SYSTEM in Subjects With Diabetes Mellitus","Inclusion Criteria:\n\n* Willing to sign an informed consent form\n* Age ≥ 18 years\n* Willing to comply to study protocol requirements (study visits with frequent venous blood sampling and deliberate insulin, glucose, ketone and lactate challenges)\n* Willing to charge the SENSOR on daily basis\n* Willing not to insert their standard CGM and\u002For insulin pump in and around the SENSOR implant site (± radius 5 cm)\\[TS\\| XR1.1\\] Diagnosed with type 1 diabetes mellitus according to the World Health Organization criteria, for at least 12 months prior to screening, on CSII therapy\n\nExclusion Criteria:\n\n* Known allergy to polydimethylsiloxane (PDMS)\n* A contraindication to undergo challenging tests (i.e., ischemic heart disease, epilepsy, panhypopituitarism, hypoadrenalism, untreated hypothyroidism)\n* History of hepatitis C or HIV or other disease transmissible by blood\n* A condition requiring or likely to require magnetic resonance imaging during the study duration\n* Female participants who are pregnant, planning on becoming pregnant or nursing\n* Coagulation disorder, wound healing and bleeding disorder or taking anticoagulant medication (oral anticoagulants; antiplatelets (such as aspirin, ticagrelor are allowed).\n* Anemia identified by a haemoglobin \\\u003C14 g\u002FdL for men or \\\u003C12 g\u002FdL for women\n* The presence of any other active implanted device\n* The presence of any other CGM sensor\u002Fpump located in the lower abdomen (other location is acceptable)\n* Waist circumference of \\>120 cm\n* Any disorder, which in the investigator's opinion might jeopardise participants' safety or compliance with the protocol.",{"count":253,"type":22},12,[25],"The purpose of the BRIGHT study is to evaluate safety and performance of the HALO SYSTEM in subjects with diabetes mellitus. The primary objectives of this clinical investigation are 1) the evaluation of sensor's performance by demonstrating sensor's accuracy and stability and 2) to confirm safe implantation of the Sensor and safety of the device during implantation.",[257,258,30,259,260,261],"Diabetes Mellitus - Type 1","Diabetes Mellitus - Type 2","Ketoacidosis, Diabetic","Hyperglycaemia (Diabetic)","Hypoglycemia (Diabetic)",[263,264,265,266,267,268,269,270],"CMM","CGM","Diabetes mellitus - type 1","Diabetes mellitus - type 2","ketoacidosis, diabetic","continuous multi-metabolite monitoring","hyperglycaemia (diabetic)","hypoglycaemia (diabetic)","2026-08-03",{"date":237,"type":43},{"date":274,"type":22},"2026-12",{"date":276,"type":22},"2027-06",{"name":278,"class":279},"Indigo Diabetes NV","INDUSTRY",{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":23,"phases":290,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":295,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":302},"100633937","phase-3-amaze-2-a-research-study-investigating-how-well-the-medicine-nnc0487-0111-helps-people-with-excess-body-weight-and-type-2-diabetes-lose-weight-100633937","NCT07533175","AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight","Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 2)","AMAZE 2","Inclusion Criteria:\n\n* Male or female (sex at birth).\n* Age 18 years or above at the time of signing informed consent.\n* Diagnosed with type 2 diabetes mellitus more than equal to (≥) 180 days before screening.\n* Treatment with lifestyle intervention, and\u002For 0-3 marketed oral antidiabetic drugs (OAD)s (metformin, α-glucosidase inhibitors (AGI), glinides, sodium-glucose cotransporter 2 inhibitor (SGLT2i), thiazolidinediones, or sulfonylureas (SU) as a single agent or in combination) according to local label. Treatment with oral antidiabetic drugs should be stable (same drug(s), dose and dosing frequency) before screening.\n* Haemoglobin A1c (HbA1c) 7-10% \\[53-86 (millimoles per mole) mmol\u002Fmol\\] (both inclusive) as measured by the central laboratory at screening.\n\nExclusion Criteria:\n\n* Renal impairment with estimated Glomerular Filtration Rate (eGFR) less than (\\\u003C) 30 milliliter per minute per meter square (mL\u002Fmin\u002F1.73 m\\^2) \\[2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula\\], at screening.\n* Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) before screening or are expected to require treatment after screening. Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.\n* Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question 8.\n* Recurrent severe hypoglycaemic episodes within the last year as judged by the investigator.\n* Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1\u002Fgastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues before screening.",{"count":289,"type":22},630,[291],"PHASE3","The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (treatment that has no active medicine in it). Which treatment participants get is decided by chance.",[30,294,145],"Overweight",{"date":237,"type":43},{"date":297,"type":43},"2026-04-13",{"date":299,"type":22},"2028-08-07",{"name":301,"class":279},"Novo Nordisk A\u002FS",74,{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":312,"conditions":313,"keywords":314,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":327,"startDateStruct":328,"completionDateStruct":329,"leadSponsor":331,"locationsCount":51},"100628578","inter-device-concordance-of-plantar-thermal-asymmetry-measurement-hik-dm-2026-100628578","NCT07463456","Inter-Device Concordance of Plantar Thermal Asymmetry Measurement (HIK-DM-2026)","Inter-Device Concordance in the Measurement of Plantar Thermal Asymmetry: Comparative Evaluation of a Low-Cost Thermographic Camera (HIKMICRO Mini2 V2) Versus a High-Resolution Camera (HIKMICRO M60) in Patients With Diabetes Mellitus","Inclusion Criteria:\n\n* Age 18 years or older.\n* Confirmed diagnosis of type 1 or type 2 diabetes mellitus.\n* Preserved plantar skin integrity at the time of the test.\n* Voluntary signature of the informed consent after receiving detailed information about the study.\n\nExclusion Criteria:\n\n* Active ulcers or open wounds in the plantar area, since exudation alters thermal emissivity.\n* Acute skin infection or extensive mycosis of the foot.\n* Previous partial amputation of the forefoot or midfoot that alters the anatomy of the regions of interest.\n* Severe peripheral arterial disease (Fontaine grade IV, critical ischemia) compromising tissue viability.\n* Physical or cognitive inability to remain in the semi-Fowler position (backrest 30 to 45 degrees) during the 15 minutes of the acclimatization protocol.\n* Intense physical activity or hydrotherapy within the 2 hours before the appointment, and caffeine intake or tobacco use within the same period, because of their vasoconstrictor effects.\n* Acute febrile state, body or tympanic temperature above 37.5 degrees Celsius at the time of the test.\n* Application of creams, moisturizing lotions, topical ointments or talcum powder to the plantar area within the 4 hours before the examination, because of the alteration of infrared emissivity and the evaporative cooling effect.",{"count":311,"type":22},130,"This cross-sectional observational study measures the inter-device concordance between two infrared thermographic cameras, a low-cost model (HIKMICRO Mini2 V2) and a high-resolution model (HIKMICRO M60), when measuring plantar skin temperature in adults with diabetes mellitus. Each participant undergoes two consecutive thermographic acquisitions, always less than 10 seconds apart, from a fixed tripod at 75 cm, under standardized environmental conditions. The order of the two cameras is randomized 1:1 at participant level (sequence A: M60 then Mini2 V2; sequence B: Mini2 V2 then M60). The primary endpoint is the agreement between the two devices for contralateral thermal asymmetry (Delta T) in each of six pre-specified plantar regions of interest (ROIs), quantified by the intraclass correlation coefficient (ICC) for absolute agreement, with the consistency ICC for mean plantar temperature (Tmean) as an exploratory endpoint.\n\nThe study is strictly metrological. Neither camera is a medical device under Regulation (EU) 2017\u002F745, no clinical decision is derived from the measurements, and the study does not evaluate the detection, diagnosis, screening or prevention of any disease. Neither device is designated as a diagnostic reference standard. Participants with diabetes mellitus are included solely because plantar thermal variability is greater in this population, which makes the inter-device comparison metrologically demanding.",[30],[315,316,317,318,319,320,321,322,323,324,325,326],"thermography","infrared","concordance","ICC","low-cost","HIKMICRO","plantar temperature","inter-device concordance","intraclass correlation coefficient","thermal asymmetry","agreement study","measurement reproducibility",{"date":179,"type":43},{"date":45,"type":22},{"date":330,"type":22},"2027-07",{"name":332,"class":50},"Eduardo Luis Martín Javier",{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":340,"enrollmentInfo":341,"targetDuration":4,"studyType":23,"phases":343,"briefSummary":344,"conditions":345,"keywords":349,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":356,"leadSponsor":358,"locationsCount":4},"100650328","cognitive-intervention-for-cognitive-impairment-100650328","NCT07747675","Cognitive Intervention for Cognitive Impairment","Cognitive Intervention to Improve Mild Cognitive Impairment in Older Adults: Randomized Double-blind Clinical Trial","Inclusion Criteria:\n\n* Affiliation with IMSS Aguascalientes Family Medicine Unit (UMF) No. 7; age 65 to 95 years; male or female; known diagnosis of type 2 diabetes mellitus; any level of education; any occupation; presence of mild cognitive impairment; availability to attend cognitive intervention sessions; and signing of informed consent.\n\nExclusion Criteria:\n\n* Patients with disabling hearing and\u002For visual impairments, patients with paralysis, and patients with severe psychiatric illness.","95 Years",{"count":342,"type":22},102,[25],"Mild cognitive impairment is characterized by cognitive dysfunction without impairment in instrumental activities of daily living, with aging being the primary risk factor. Cognitive interventions employ stimulation and training techniques to address this impairment.\n\nObjective: To determine the effect of a cognitive intervention on mild cognitive impairment in older adults with type 2 diabetes mellitus.\n\nMethods: A double-blind, randomized clinical trial involving 102 patients, who will be assigned to either a control group or an intervention group. Data collection will utilize a sociodemographic profile questionnaire and the Montreal Cognitive Assessment (MoCA). The cognitive intervention will be implemented over an average period of two months per subgroup, consisting of eight weekly, 60-minute sessions. Analysis will be conducted using descriptive statistics, and a linear mixed-effects model for repeated measures will be applied to evaluate the intervention's effect.",[346,347,348,30],"Cognitive Intervention","Mild Cognitive Impairment","Elderly Adults",[347,350,351,30],"Cognitive intervention","Elderly adults","2026-07-31",{"date":354,"type":43},"2026-08-05",{"date":271,"type":22},{"date":357,"type":22},"2026-10-15",{"name":359,"class":360},"Instituto Mexicano del Seguro Social","OTHER_GOV",{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":17,"minAge":367,"maxAge":4,"enrollmentInfo":368,"targetDuration":370,"studyType":115,"phases":4,"briefSummary":371,"conditions":372,"keywords":374,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":378,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":382,"locationsCount":384},"100617321","omnipod-5-a-french-prospective-multicentric-study-in-real-world-optimal-b-100617321","NCT07317102","Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)","Inclusion Criteria:\n\n* Patient with T1D aged ≥ 2 years.\n* Patient prescribed, less than a year ago, a commercially available confi guration of the Omnipod 5 System using a FreeStyle Libre 2 Plus sensor.\n* Patient has never used the Omnipod 5 System prior to inclusion.\n* Patient has not objected to the use of their personal data for this study.\n* Patient or legal guardian has an email address and mobile phone number.\n* Patient (and legal guardians if the patient is a minor) is able to understand study information and Non-Opposition form.\n* Patient (and legal guardians if the patient is a minor) is able to understand and complete questionnaires in French.\n* Patient is covered by the local social security system\n\nExclusion Criteria:\n\n* Patient is currently pregnant.\n* Patient presents an allergy to the materials of the Omnipod 5 System (patch, cannula, CGM).\n* Patient is unable to be followed by the same investigation site for the duration of the study or is unwilling or unable to maintain contact with the healthcare professional.\n* Patient is already participating in a clinical trial or in another study precluding their participation in other studies.\n* Adult under guardianship, curatorship or tutorship.\n* Adult otherwise deprived of liberty.","2 Years",{"count":369,"type":22},152,"12 Months","The purpose of this postmarket clinical investigation is to evaluate the levels of glycemic control, quality of life, and satisfaction, as well as the patient experience, and acute diabetes complication rates provided by the Omnipod 5 Automated Insulin Delivery System (referred to as the Omnipod 5 System) in a real-world setting.",[205,373,30],"Type 1 Diabetes",[375,376,377],"Omnipod","Automated Insulin Delivery","Post-market Registry",{"date":271,"type":43},{"date":380,"type":43},"2026-03-16",{"date":47,"type":22},{"name":383,"class":279},"Insulet Corporation",24,{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":17,"minAge":59,"maxAge":393,"enrollmentInfo":394,"targetDuration":4,"studyType":23,"phases":396,"briefSummary":398,"conditions":399,"keywords":402,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":166},"100572186","phase-2-pioglitazone-versus-empagliflozin-for-chronic-pancreatitisrecurrent-acute-pancreatitisacute-pancreatitis-associated-diabetes-mellitus-100572186","NCT06729996","Pioglitazone Versus Empagliflozin for Chronic Pancreatitis\u002FRecurrent Acute Pancreatitis\u002FAcute Pancreatitis Associated Diabetes Mellitus","Randomized, Parallel Group, Dose Escalation Trial of Pioglitazone Versus Empagliflozin for Chronic Pancreatitis\u002FRecurrent Acute Pancreatitis\u002FAcute Pancreatitis Associated Diabetes Mellitus: The PEP-DM Trial","PEP-DM","Inclusion Criteria:\n\n1. Age ≥18-80 years at the time of enrollment.\n2. RAP or CP with DM diagnosed before or after CP diagnosis (Confirmed CP on imaging or RAP based on PROCEED study criteria, or acute pancreatitis followed by diabetes (AP-DM) and confirmed DM as per ADA criteria or clinically diagnosed with DM and on antihyperglycemic therapy)\n3. Able to provide written informed consent and participate in longitudinal follow-up\n4. A Stable retinal exam within 1 year prior to enrollment unless new onset diabetes was diagnosed within 6 months prior to study enrollment. If an eye exam within the past year is not available but the most recent exam is stable, a standard of care eye exam needs to be scheduled during the study period.\n5. HbA1c level 6.5-10.5% at screening visit.\n6. Current ongoing treatment with metformin and\u002For insulin and other antihyperglycemic medications will be accepted at screening. Patients will be willing to safely withdraw one or more study medication or mealtime insulin under the supervision of the study team by the time of screening. The patients clinical team will be informed promptly. Patients not on any antihyperglycemic medications are also eligible.\n\n   a. If on a GLP-1 medication (e.g., semaglutide \\[Ozempic, Wegovy, Rybelsus\\], liraglutide, dulaglutide, exenatide, tirzepatide, etc.), the patient must be on a stable dose for at least 3 months prior to enrollment, with stable weight status at the time of enrollment and the GLP-1 dose cannot be escalated during the study period.\n7. Willing to perform blood glucose and ketone testing on study provided meters as per study protocol.\n\nExclusion Criteria:\n\n1. Inability to take PIO or EMPA due to prior hypersensitivity or allergic reaction or current use of medications with potential for drug-drug interactions (Pioglitazone: Drug information - UpToDate, Empagliflozin: Drug information - UpToDate)\n2. Patients on PIO or EMPA at the time of screening\n3. Diagnosed with Type 1 Diabetes\n4. Pregnancy or lactation in women (positive urine pregnancy test at screening will lead to exclusion)\n5. History of bleeding disorders (e.g., Hemophilia A (factor VIII deficiency), hemophilia B (factor IX deficiency), von Willebrand disease, platelet disorders etc)\n6. Presence of hepatic impairment, ALT \\>3 x ULN with no etiology known at the time of enrollment or any evidence of acute\u002Fchronic liver disease\n7. Ongoing treatment for any malignancy requiring systemic treatment (non-melanoma skin cancers treated in dermatologists' office would be acceptable)\n8. Presence of osteoporosis without definitive treatment according to PI discretion.\n9. Recent inflammatory illness within the 30 days preceding enrollment (e.g.: URTI, episode of AP, etc)\n10. History of heart failure classified by NYHA as Class III or greater\n11. History of kidney dysfunction classified by an eGFR of \\\u003C30 mL\u002Fmin\u002Fmin\n12. Participation in any clinical trial within 30 days before screening for an approved or non-approved investigational medical product.\n13. Active alcohol dependence or chemical dependence including tobacco based on investigator discretion\n14. On a ketogenic diet\n15. Autoimmune pancreatitis, obstructive pancreatitis, and prior surgery of pancreas (Whipple procedure, total pancreatectomy, and distal pancreatectomy)\n16. Any condition which could jeopardize participant safety as per investigator opinion, (hemolytic anemia limiting A1c reliability, any evidence of fluid overload, presence of Congestive heart failure etc).\n17. Recent DKA or signs of decompensated diabetes in last 6 months or increased β hydroxybutyrate levels (\\>0.4 mmol\u002FL) at screening.","80 Years",{"count":395,"type":22},50,[397],"PHASE2","The purpose of this study is to evaluate efficacy of pioglitazone (PIO) versus empagliflozin (EMPA) to improve glycemic control in people with Chronic Pancreatitis (CP) or Recurrent Acute Pancreatitis (RAP) or Acute Pancreatitis (AP) associated with Diabetes Mellitus (DM). To evaluate mixed meal response in PIO versus EMPA group to better understand physiology of both therapies in CP-DM.",[400,401,30],"Pancreatitis, Chronic","Pancreatitis, Acute",[403,36,404,405,406],"pancreatitis","diabetes mellitus","empagliflozin","pioglitazone","2026-07-27",{"date":409,"type":43},"2026-07-29",{"date":411,"type":43},"2025-05-29",{"date":413,"type":22},"2027-05-31",{"name":415,"class":50},"Mayo Clinic",{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":110,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":423,"targetDuration":4,"studyType":23,"phases":425,"briefSummary":426,"conditions":427,"keywords":434,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":442,"locationsCount":51},"100366758","phase-2-nautical-effect-of-natriuretic-peptide-augmentation-on-cardiometabolic-health-in-black-individuals-100366758","NCT04055428","NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals","The Effects of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals (NAUTICAL)","Inclusion Criteria:\n\n* Adults: Age more than or equal to 18 years of age\n* Self-identified race\u002Fethnicity as African-American or Black\n* Blood pressure: 120-160\u002F80-100 mmHg\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding or who can become pregnant and not practicing an acceptable method of birth control during the study (including abstinence)\n* Have any past or present history of cardiovascular diseases (stroke, myocardial infarction, heart failure, transient ischemic attack, angina, or cardiac arrhythmia)\n* BP more than 160\u002F100 mmHg\n* BMI \\>45 kg\u002Fm2\n* History of diabetes or fasting plasma glucose \\>=126 mg\u002FdL or HbA1C\\>=6.5%\n* History of angioedema\n* Current or past (\\\u003C12 months) history of smoking\n* Estimated GFR \\\u003C 60 ml\u002Fmin\u002F1.73 m2; albumin-creatinine ratio ≥30 mg\u002Fg\n* Hepatic Transaminase (AST and ALT) levels \\>3x the upper limit of normal\n* Significant psychiatric illness or seizure disorder\n* More than 2 Alcoholic drinks daily\n* Anemia (men, Hct \\\u003C 38%, Hb\\\u003C13 g\u002FdL; women, Hct \\\u003C36%, Hb \\\u003C12 g\u002FdL)\n* Inability to exercise on a treadmill",{"count":424,"type":22},200,[397],"Black individuals are more likely to have decreased insulin sensitivity which results in a high risk for the development of cardiometabolic disease. The reasons for this are incompletely understood. Natriuretic peptides (NPs) are hormones produced by the heart that play a role in regulating the metabolic health of an individual. Low circulating level of NPs is an important contributor to increased risk for diabetes. The NP levels are relatively lower among Black individuals thus affecting their metabolic health and putting them at a higher risk for diabetes. This study aims to test the hypothesis that by augmenting NP levels using sacubitril\u002Fvalsartan, among Black Individuals one can improve their metabolic health (as measured by insulin sensitivity \\& energy expenditure) and help establish the role of NPs in the underlying mechanism behind increased risk for cardiometabolic disease in these population.",[30,428,429,430,431,432,433],"Cardiovascular Diseases","Insulin Sensitivity\u002FResistance","Metabolic Disease","Natriuretic Peptides","Metabolism","Energy Expenditure",[431,205,435,433],"Insulin Sensitivity","2026-07-24",{"date":438,"type":43},"2026-07-28",{"date":440,"type":43},"2020-08-15",{"date":413,"type":22},{"name":443,"class":50},"University of Alabama at Birmingham",{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":12,"sex":17,"minAge":59,"maxAge":451,"enrollmentInfo":452,"targetDuration":4,"studyType":23,"phases":454,"briefSummary":455,"conditions":456,"keywords":457,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":469,"locationsCount":51},"100596426","cgm-use-in-heart-failure-100596426","NCT07045298","CGM Use in Heart Failure","Real-Time Continuous Glucose Monitoring for the Management of Patients With Type 2 Diabetes and Acutely Decompensated Heart Failure","Inclusion Criteria:\n\n* Adults 18 to 90 years admitted with a diagnosis of acute decompensated heart failure (ADHF), New York Heart Association (NYHA) class II, III, or IV symptoms (Aim 1) and discharged with a clinical diagnosis of ADHF (Aim 2).\n* Patients with diabetes treated with diet alone or oral antidiabetic agents, Glucagon-like peptide-1 receptor agonists (GLP1-RAs), or insulin after discharge\n\nExclusion Criteria:\n\n* Age \\\u003C 18 or \\> 90 years;\n* Patients with a history of type 1 diabetes;\n* Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study;\n* Patients on ventricular assist devices;\n* History of a heart transplant or listed for a heart transplant;\n* History of cardiac surgery (within 90 days before enrollment) or planned cardiac interventions within the following 6 months;\n* Female participants who are pregnant or breastfeeding at the time of enrollment into the study;\n* Hospice care or expected life expectancy of less than 6 months;\n* Patients who are expected to require Magnetic Resonance Imaging (MRI) procedures during hospitalization or after discharge.","90 Years",{"count":453,"type":22},140,[25],"Heart failure (HF) is a major cause of hospital admissions in the US, with over 6 million hospital days annually.\n\nMore than 40% of hospitalized patients with HF have diabetes mellitus (DM), which increases the risk of recurrent hospitalizations for HF with reduced and preserved ejection fraction by more than two-fold. Current methods for assessing glycemic control do not consider fluctuations in blood glucose levels, known as glycemic variability. High glycemic variability is a poor prognostic marker for HF re-hospitalizations. Given the significant prevalence and impact of DM in individuals with HF, it is crucial to examine whether improving glycemic control and avoiding hypoglycemia could lead to a decrease in HF readmissions. Real-time continuous glucose monitoring (rt-CGM), which provides glucose measurements as frequently as every 5 minutes, has improved glycemic control in insulin-treated adults with DM compared to the standard of care, capillary point-of-care blood glucose testing (POC). Researchers will monitor participants during their hospital stay and 3 months after discharge.",[230,30],[458,459,460,461,462],"Continuous Glucose Monitoring (CGM) system","Acute Decompensated Heart failure","Glycemic control","Inpatient","Bedside point-of-care capillary glucose monitoring","2026-07-21",{"date":465,"type":43},"2026-07-22",{"date":467,"type":22},"2026-11",{"date":47,"type":22},{"name":470,"class":50},"Emory University",{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":110,"sex":478,"minAge":479,"maxAge":18,"enrollmentInfo":480,"targetDuration":4,"studyType":23,"phases":482,"briefSummary":483,"conditions":484,"keywords":488,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":51},"100542041","phase-2-smart-walk-a-culturally-tailored-smartphone-delivered-physical-activity-intervention-for-african-american-women-100542041","NCT06337708","Smart Walk: A Culturally Tailored Smartphone-Delivered Physical Activity Intervention for African American Women","Smart Walk: An Efficacy Trial of a Culturally Tailored Smartphone-Delivered Physical Activity Intervention for African American Women","Inclusion Criteria:\n\n* Self-reported African American\u002FBlack female\n* Aged of 24-65 years\n* Insufficiently Active (\\\u003C 60 minutes of moderate-to-vigorous physical activity per week as measured by Exercise Vital Sign Questionnaire)\n* BMI \\> 25 kg\u002Fm2\n* English speaking and reading\n* Ownership of a smartphone with the ability to download applications (i.e., apps)\n* Ownership of a smartphone with the ability to receive text messages\n* Willingness to receive a physical activity intervention delivered through their smartphone\n* Willingness to include their first name or create an alias to be used on their profile page on the Smart Walk app\n\nExclusion Criteria:\n\n* Plans to relocate out of Phoenix area in next 12 months\n* Endorsing an item on the Physical Activity Readiness Questionnaire (PAR-Q), unless a doctor's note for study participation in provided\n* Resting systolic blood pressure greater than 180 mmHG and\u002For a diastolic blood pressure greater than 120 mmHG , as assessed at baseline or at any other study assessment\n* Self-reported participation in another diet or weight loss study at screening\n* Pregnant or planning to become pregnant in the next 12 months","FEMALE","24 Years",{"count":481,"type":22},210,[397],"The purpose of this study is to test a culturally tailored, smartphone-delivered intervention designed to increase physical activity and reduce risk for heart disease and type 2 diabetes among African American women.",[150,485,486,30,487],"Exercise","Heart Diseases","Physical Inactivity",[489,490,491,492,493,494,495,496,36],"mHealth","women's health","health equity","African American women","Black women","exercise","physical activity","heart disease","2026-07-16",{"date":499,"type":43},"2026-07-17",{"date":501,"type":43},"2024-04-08",{"date":503,"type":22},"2029-03-31",{"name":505,"class":50},"Arizona State University",{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":12,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":23,"phases":514,"briefSummary":515,"conditions":516,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":51},"100593441","inpatient-use-of-personal-continuous-glucose-monitor-cgm-to-improve-diabetes-mellitus-control-100593441","NCT07006480","Inpatient Use of Personal Continuous Glucose Monitor (CGM) to Improve Diabetes Mellitus Control","Inclusion Criteria:\n\n1. Patients with ages above 18 years old at the time of informed consent.\n2. Male or female\n3. Admitted to non-ICU setting in brick-and-mortar medical and surgical ward or admitted to Advanced Care at Home Program.\n4. Admitted under observation or inpatient status.\n5. Expected to remain in the hospital for more than 48 hours.\n6. Patients that are using a transcutaneous or implantable real time CGM as outpatient and are bringing it to the hospital.\n7. Patients with diagnosis of diabetes mellitus or hyperglycemia requiring treatment with SQ insulin in the hospital either with multiple daily injections or subcutaneous infusion of insulin via insulin pump.\n\nExclusion Criteria:\n\n1. Participants unable to provide informed medical consent.\n2. Participants admitted to Intensive Care Units (ICU). Enrollment is possible after transferring out of the ICU.\n3. Actively being treated for DKA (diabetes ketoacidosis) or HHS (hyperosmolar hyperglycemic state)\n4. Patients with a diagnosis of liver cirrhosis.\n5. Patients with a diagnosis of ESRD or Acute Renal Failure on hemodialysis or peritoneal dialysis.\n6. Patients with planned MRI or surgical procedure. Enrollment is possible after MRI or surgery.\n7. Participants with allergy to medical grade adhesive or medical tape.\n8. Participants who are pregnant, wanting to become pregnant, or nursing during study period.\n9. Participants using Medtronic and Dexcom sensors and taking acetaminophen more than 4g per day or more than 1gm every 6 hours.\n10. Participants using Dexcom sensors and taking hydroxyurea.\n11. Participants using Libre sensors and taking over 500 mg of ascorbic acid.\n12. Patients using Eversense sensors and taking tetracycline type of antibiotics.\n13. Participants actively enrolled in other studies addressing their CGM use unless express permission is obtained from prior study research team principal investigator or co-principal investigator.",{"count":513,"type":22},150,[25],"The purpose of this research is to prove that data generated by your real-time personal continuous glucose monitors CGMs brought in the hospital at the time of hospitalization can be monitored and safely used to guide insulin therapy aiming to improve glycemic control and to diminish the hypoglycemia and hyperglycemia episodes without negatively affecting patients' satisfaction, providers and your nurses satisfaction with how glucose is monitored and treated in the hospital.",[30],"2026-07-14",{"date":519,"type":43},"2026-07-15",{"date":521,"type":43},"2025-10-01",{"date":523,"type":22},"2027-02-09",{"name":415,"class":50},{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":531,"eligibilityCriteria":532,"healthyVolunteers":110,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":533,"targetDuration":4,"studyType":23,"phases":535,"briefSummary":536,"conditions":537,"keywords":538,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":542,"completionDateStruct":543,"leadSponsor":545,"locationsCount":4},"100647095","otago-exercises-in-diabetes-mellitus-examining-its-effectiveness-100647095","NCT07705958","OTAGO Exercises in Diabetes Mellitus Examining Its Effectiveness","OTAGO Exercises in Individuals Diagnosed With Diabetes Mellitus Examining Its Effectiveness","OTAGO in DM","Inclusion Criteria:\n\n* Cases diagnosed with Diabetes Mellitus,\n* Cases that do not have any orthopedic\u002Fneurological\u002Fcardiopulmonary disease other than Diabetes Mellitus that will directly affect the evaluation results,\n* Having agreed to participate in the study voluntarily,\n* Having been diagnosed with Type 2 DM for at least 1 year\n\nExclusion Criteria:\n\n* Not agreeing to participate in the study,\n* Individuals with additional diseases other than DM that will affect the evaluations,\n* Having a smoking habit or history\n* Restriction in joint movements or any orthopedic\u002Fneurological\u002Fcardiopulmonary disease that may cause this,\n* Not being able to cooperate,\n* Having vision loss,\n* Having hearing loss,\n* Having a diabetic ulcer on the foot,",{"count":534,"type":22},56,[25],"Diabetes Mellitus (DM) is a chronic metabolic disease characterized by hyperglycemia, which occurs in insulin deficiency or when the body cannot effectively use the insulin produced. Moreover, according to the \"Global Report on Diabetes\" data published by the World Health Organization (WHO) in 2016, it is an important public health problem, one of the four priority non-communicable diseases (1, 2). In addition to the high mortality rates caused by complications due to DM, it is also known that it can cause low quality of life and many other additional problems in individuals. Possible complications are chronic and serious problems such as heart attack, risk of stroke, kidney failure, vision loss and nerve damage. One of the most common and most disabling complications is neuropathy. It should also be noted that approximately half of diabetic neuropathy is asymptomatic and patients diagnosed with DM may have neuropathy due to causes other than diabetes (2). These complications and damage that DM can cause can lead to decreased blood flow combined with neuropathy; As a result, foot ulcers and infections may occur; Amputation rates may increase. In addition to such additional complications that diabetic neuropathy may cause, due to all these; Loss of protective plantar sensation may also occur (3). This loss of protective sensation may lead to cutaneous deficits in the lower extremities, loss of muscle strength and reflexes, and gait and balance disorders (4). The mechanism that makes an important contribution to functional joint stability and the continuity of this stability, along with the feedback mechanisms required to ensure neuromuscular control, is proprioception, which includes joint movement (kinesthesia) and joint position sense (EPH) and is a subunit of the somatosensory system (5-7). . Rehabilitation with various injuries and other clinical conditions; Clinical studies to determine its effects on joint proprioception, neuromuscular control and balance have mostly focused on knee and ankle joints (5). The main reason for this can be attributed to the great importance of the knee and ankle joints in the lower extremities in maintaining general body kinematics and balance (8). Additionally, it has been reported in the literature that EPH and plantar sensory loss are observed in individuals diagnosed with DM, and these complications may cause additional problems (10, 12, 18-22). Additionally, many studies in the literature on this subject have been conducted in individuals with diabetic neuropathy, and changes in functional parameters such as plantar sensation, proprioception, muscle strength and balance have been examined (10, 19, 20, 22, 23). However, it has been found that not only individuals with neuropathy but also individuals diagnosed with DM without neuropathy have balance disorders (24).\n\nThere are many studies in the literature about the effects of different exercise training on proprioception. In general, studies have reported that exercise training without weight bearing on the extremity has no effect on proprioception, but as a result of exercises performed with weight bearing on the extremity, a significant improvement was noted in both proprioceptive performance and muscle strength (25). In one of the most recent studies on this subject, it was stated that proprioceptive sensitivity increased in individuals with knee osteoarthritis with 8-week squat strengthening training performed by transferring weight to the extremity (26). Additionally, there are studies in the literature reporting different results regarding the effects of stretching exercises on proprioceptive performance. Some studies have reported that static stretching has no effect on proprioception, while others have reported that it has a positive effect on proprioception (27,28).\n\nThe Otago Exercise Program is an evidence-based, home-based, individually tailored strength and balance retraining program. Research shows that the Otago Exercise Program is effective in reducing the risk of death and the incidence of falls in older adults over a one-year period. In one study, falls were reduced by 35% in older adults has been reported(29)\n\nThis study was planned to examine the effectiveness of balance exercises given as a home program to individuals diagnosed with Type 2 DM.",[30,28],[539,32,90],"balance","2026-07-10",{"date":519,"type":43},{"date":98,"type":22},{"date":544,"type":22},"2026-12-01",{"name":546,"class":50},"Pamukkale University",{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":110,"sex":17,"minAge":554,"maxAge":4,"enrollmentInfo":555,"targetDuration":557,"studyType":115,"phases":4,"briefSummary":558,"conditions":559,"keywords":561,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":568,"completionDateStruct":569,"leadSponsor":571,"locationsCount":4},"100646104","perioperative-hypoglycemia-in-diabetic-patients-undergoing-vitrectomy-a-masked-cgm-prospective-observational-study-100646104","NCT07696910","Perioperative Hypoglycemia in Diabetic Patients Undergoing Vitrectomy: a Masked CGM Prospective Observational Study","Incidence of Perioperative Hypoglycemia Assessed by Masked Continuous Glucose Monitoring in Patients With Diabetes Undergoing Vitrectomy: a Prospective Observational Cohort Study","Inclusion Criteria:\n\n1. Adults aged 19 years or older\n2. Diagnosed with diabetes mellitus\n3. Scheduled to undergo pars plana vitrectomy (TPPV)\n4. Able to provide written informed consent\n\nExclusion Criteria:\n\n1. CGM sensor placement not feasible\n2. Known allergy to the CGM sensor\n3. Unable to obtain valid CGM data\n4. Unable to provide voluntary informed consent","19 Years",{"count":556,"type":22},85,"3 Months","Patients with diabetes are at increased risk of perioperative glycemic disturbances due to preoperative fasting, the surgical stress response, and the use of insulin or oral hypoglycemic agents. Hypoglycemia, in particular, is an important clinical concern associated with neurological injury and cardiovascular complications. In routine practice, intraoperative glucose monitoring often relies on intermittent fingerstick testing or blood gas analysis, and these intermittent methods may fail to detect hypoglycemic episodes that occur during and immediately after surgery.\n\nContinuous glucose monitoring (CGM), which estimates glucose concentrations from interstitial fluid, allows continuous tracking of glycemic trends and may provide a more precise assessment of glycemic variability and hypoglycemia in the perioperative period. Although current guidelines recommend periodic intraoperative glucose measurement in patients with diabetes-especially those receiving insulin-glucose monitoring is frequently omitted during relatively short and stable ophthalmic procedures such as vitrectomy. Because vitrectomy is commonly performed in patients with diabetes, perioperative hypoglycemia in this population may go undetected.\n\nThis is a single-center, prospective, observational cohort study conducted in patients with diabetes undergoing pars plana vitrectomy (TPPV). A masked CGM device (FreeStyle Libre 2®, an approved continuous glucose monitor) is applied for observational purposes only and does not influence clinical care. The sensor is placed on the upper arm before surgery. After an approximately one-hour warm-up period, glucose data are collected at 15-minute intervals from the completion of CGM warm-up until discharge from the post-anesthesia care unit (PACU); this interval defines the perioperative period for data collection. Throughout this period the CGM operates in a masked mode-no reader is provided, the device is not linked to the participant's smartphone, and alarms are disabled-so that real-time glucose values are not displayed to clinicians or participants. All glycemic management follows the existing standard of care based on point-of-care testing (POCT), and CGM data do not contribute to clinical decision-making. After all participants have completed data collection, CGM data are unblinded and analyzed.\n\nThe primary objective is to estimate the incidence of perioperative hypoglycemia, defined as a CGM glucose value below 70 mg\u002FdL (Level 1), during the perioperative period. Secondary objectives include the incidence of clinically significant hypoglycemia (below 54 mg\u002FdL, Level 2); indices of glycemic variability (Time Below Range, maximum and minimum glucose, and glucose excursion); identification of clinical risk factors associated with perioperative hypoglycemia (such as age, diabetes characteristics, HbA1c, insulin use, fasting duration, and operative time); the exploratory association between perioperative hypoglycemia and postoperative ophthalmic outcomes (changes in best-corrected visual acuity and ophthalmic complications such as recurrent vitreous hemorrhage, retinal redetachment, elevated intraocular pressure, and the need for additional procedures); and an exploratory, opportunistic concordance analysis between standard-of-care POCT glucose values and time-matched CGM values (within ±5 minutes). Hypoglycemia is classified according to ADA\u002FDanne et al. criteria.\n\nEligible participants are adults aged 19 years or older with diabetes who are scheduled for vitrectomy and able to provide written informed consent. Participants are excluded if CGM sensor placement is not feasible, if they have a known sensor allergy, if valid data cannot be obtained, or if voluntary informed consent is not possible. Based on the institution's monthly surgical volume and the estimated proportion of patients with diabetes, a target enrollment of 85 participants over a 12-month study period is considered feasible. Postoperative ophthalmic outcomes are assessed using medical records from routine outpatient follow-up visits (for example, at approximately one week and one to three months after surgery) without any additional study-specific visits.\n\nBecause the primary aim is to estimate the incidence of perioperative hypoglycemia, ophthalmic outcomes and POCT-CGM concordance are analyzed as exploratory endpoints. This study aims to characterize the limitations of current perioperative glucose monitoring strategies and to provide foundational data for future risk-based monitoring strategies and CGM-based interventional research.",[30,560],"Hypoglycemia",[562,563,90,564,565],"Continuous glucose monitoring (CGM)","Perioperative hypoglycemia","Vitrectomy","Blood glucose monitoring","2026-07-08",{"date":540,"type":43},{"date":519,"type":22},{"date":570,"type":22},"2027-07-15",{"name":572,"class":50},"Yonsei University",{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":577,"acronym":4,"eligibilityCriteria":578,"healthyVolunteers":110,"sex":17,"minAge":579,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":23,"phases":582,"briefSummary":583,"conditions":584,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":51},"100520015","care-transitions-app-for-patients-with-multiple-chronic-conditions-100520015","NCT06051058","Care Transitions App for Patients With Multiple Chronic Conditions","Inclusion Criteria:\n\n* Adult patients (55+) with a Brigham PCP or appointment in one of the 15 locations discharging from a BWH general medicine unit\n* Discharging to home, home health care service or assisted living\n* Fluent in spoken English in patient or healthcare proxy\n* Patients with at least one of the conditions listed below + one additional chronic condition on the problem list.\n* Patient with heart failure on the problem list\n* Patient with type 2 diabetes on the problem list\n* Patient with chronic kidney disease on the problem list\n\nExclusion Criteria:\n\n* Adult patients (55+) with Westwood, Pembroke, or Transition Clinic PCP admitted to ICU, OBGYN, Surgical, Cardiology, Oncology, Orthopedics, or other Specialty Unit\n* Pregnant\n* Prisoner, institutionalized individual or in police custody\n* Discharge planned within 3 hours of screening\n* Patient too ill to participate or with active psychosis\u002Fserious mental illness, delirium, or severe dementia\n* Not fluent in spoken English in patient and health proxy\n* Unlikely to be discharged to home\n* Lacks a device capable of accessing the app\n* Lack of a working telephone for 30-day follow-up","55 Years",{"count":581,"type":22},798,[25],"The objective of this study is to widely implement and evaluate the Care Transitions App in a randomized controlled trial. The app the investigators designed for patients with multiple chronic conditions has four envisioned modules: 1) falls-reduction content, 2) a digital post-discharge transitional care plan (e.g., after hospital care plan, including education, medications, follow-up appointments, warning signs to watch for, nutrition, and other care plan activities), 3) a new module for patients with MCC (diabetes, congestive heart failure, and chronic kidney disease) including condition-specific post-discharge care plans with relevant symptom management activities, 4) a new post-discharge report module which summarizes key care transition findings and allows for patients to enter notes and questions for their providers and their own goals for recovery.",[230,585,205,30,586],"Congestive Heart Failure","Chronic Kidney Diseases",{"date":588,"type":43},"2026-07-09",{"date":590,"type":43},"2024-10-08",{"date":592,"type":22},"2027-12",{"name":594,"class":50},"Brigham and Women's Hospital",{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":599,"acronym":4,"eligibilityCriteria":600,"healthyVolunteers":110,"sex":17,"minAge":59,"maxAge":601,"enrollmentInfo":602,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":604,"conditions":605,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":606,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":51},"100336291","tbinger-diabetes-mellitus-database-tuedid-100336291","NCT03658512","Tübinger Diabetes Mellitus Database (TUEDID)","Inclusion Criteria:\n\n* \\>18 years\n\nExclusion Criteria:\n\n* no written informed consent","85 Years",{"count":603,"type":22},1000,"Diabetes mellitus is a widespread disease with increasing prevalence worldwide. Patients with diabetes can develop multiple late complications such as neuropathy, retinopathy, nephropathy and cardiovascular comorbidities. So far, there are no reliable predictive tools or markers to estimate if, when and to what extent a patient with diabetes develops late complications. For the patients quality of life and for health economic reasons an improved risk assessment would be desirable. The prospective TUEDID study will characterize diabetic patients to look out for parameters the predict progression of diabetes and its complications.",[30],{"date":588,"type":43},{"date":608,"type":43},"2018-02-05",{"date":610,"type":22},"2035-02-01",{"name":612,"class":50},"University Hospital Tuebingen",{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":619,"eligibilityCriteria":620,"healthyVolunteers":12,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":621,"targetDuration":4,"studyType":23,"phases":622,"briefSummary":623,"conditions":624,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":635},"100601857","streamlined-denervation-with-spyral-for-an-optimized-treatment-spyral-swyft-in-subjects-with-uncontrolled-hypertension-100601857","NCT07115953","Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension","Sub-study of SPYRAL AFFIRM: Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT)","SWYFT","Inclusion Criteria:\n\n1. Individual is diagnosed with hypertension and has a baseline office systolic blood pressure ≥140 mmHg\n2. Individual has a baseline office diastolic blood pressure ≥ 90 mmHg\n3. Individual has an average systolic baseline home blood pressure ≥135 mmHg (with ≥7 days of valid pre-procedure measurements)\n4. Individual has a valid 24-hour Ambulatory Blood Pressure Measurement at baseline\n\nExclusion Criteria:\n\n1. Individual lacks appropriate renal artery anatomy\n2. Individual has undergone prior renal denervation\n3. Individual has a documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement\n4. Individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea\n5. Individual has an estimated glomerular filtration rate (eGFR) of \\\u003C45 mL\u002Fmin\u002F1.73m2\n6. Individual has one or more episode(s) of orthostatic hypotension\n7. Individual is pregnant, nursing or planning to become pregnant\n8. Individual has documented primary pulmonary hypertension\n9. Individual has documented type 1 diabetes mellitus or poorly-controlled type 2 diabetes mellitus with glycosylated hemoglobin greater than 8.0%",{"count":311,"type":22},[25],"The purpose of the SPYRAL SWYFT sub-study is to evaluate whether renal denervation with the Symplicity Spyral system performed in the main and first order branch renal arteries yields a shorter procedure time and is as effective in reducing blood pressure than the procedural approach used in the SPYRAL HTN-ON MED and SPYRAL PIVOTAL - SPYRAL HTN-OFF MED clinical studies in an uncontrolled hypertensive population.",[143,625,428,586,30],"Vascular Diseases","2026-06-29",{"date":628,"type":43},"2026-06-30",{"date":630,"type":43},"2025-09-22",{"date":632,"type":22},"2029-12-31",{"name":634,"class":279},"Medtronic Vascular",21,{"id":637,"slug":638,"hasResults":12,"nctId":639,"briefTitle":640,"officialTitle":641,"acronym":642,"eligibilityCriteria":643,"healthyVolunteers":110,"sex":17,"minAge":644,"maxAge":19,"enrollmentInfo":645,"targetDuration":4,"studyType":23,"phases":647,"briefSummary":648,"conditions":649,"keywords":653,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":661,"lastUpdatePostDateStruct":662,"startDateStruct":663,"completionDateStruct":665,"leadSponsor":667,"locationsCount":51},"100639438","uppsala-self-screening-of-cardiovascular-health-100639438","NCT07614659","Uppsala Self-Screening of Cardiovascular Health","Uppsala Self-Screening of Cardiovascular Health: A Randomized Controlled Trial of Home-Based Multimodal Cardiovascular Screening Versus Usual Care in Middle-Aged and Older Adults","U-SCREEN","Inclusion Criteria:\n\n* Resident in Region Uppsala, Sweden\n* Turning 50, 55, 60, 65, 70 or 75 years during recruitment period\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Protected identity","50 Years",{"count":646,"type":22},45000,[25],"U-SCREEN is a randomized controlled trial evaluating whether systematic home-based multimodal screening for cardiovascular risk conditions, offered to residents in Region Uppsala turning 50, 55, 60, 65, 70 or 75 years of age, can identify clinically actionable cardiovascular risk factors more effectively than usual care. Participants randomized to the screening arm receive a home blood pressure measurement device, a dried blood spot sampling kit (for ApoB, HbA1c and creatinine), and a digital questionnaire. The control arm receives usual care. Recruitment runs 2024-2027 with a target identification of 10,000 cardiovascular risk conditions.",[428,143,650,30,651,652],"Dyslipidemias","Atrial Fibrillation","Chronic Kidney Disease",[654,655,656,657,658,659,660],"Population screening","Cardiovascular prevention","Home blood pressure monitoring","Dried blood spot","Digital health","Pragmatic trial","Register-based randomized controlled trial","2026-06-26",{"date":628,"type":43},{"date":664,"type":43},"2025-02-01",{"date":666,"type":22},"2037-12",{"name":668,"class":50},"Johan Sundström",{"id":670,"slug":671,"hasResults":12,"nctId":672,"briefTitle":673,"officialTitle":674,"acronym":4,"eligibilityCriteria":675,"healthyVolunteers":12,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":676,"targetDuration":4,"studyType":23,"phases":678,"briefSummary":679,"conditions":680,"keywords":681,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":686,"lastUpdatePostDateStruct":687,"startDateStruct":689,"completionDateStruct":691,"leadSponsor":693,"locationsCount":51},"100635106","spark-cgm-implementation-100635106","NCT07548372","SPARK-CGM Implementation","Supporting Primary Care Adoption, Resources, and Knowledge for Continuous Glucose Monitoring","Inclusion Criteria:\n\nClinic level:\n\n* All adult Montefiore primary care sites\n* Clinician and clinic staff will be eligible if they provide direct patient care or are involved in CGM prescribing, authorization, onboarding, or education at participating primary care clinics. Eligible clinicians include physicians, nurse practitioners, physician assistants, and clinicians in training. Eligible clinic staff may include nurses, medical assistants, and other relevant administrative staff\n\nPatient level:\n\n* Age 18 years or older\n* Receive primary care at participating sites\n* Diagnosis of any diabetes mellitus\n* Treated with insulin therapy\n\nExclusion Criteria:\n\nClinic level:\n\n\\- Sites participating in pilot phase of CGM initiative\n\nPatient level:\n\n\\- Existing CGM prescription within 24 months before the study start",{"count":677,"type":22},20000,[25],"Continuous glucose monitoring (CGM) is a technology that helps individuals with diabetes track their sugar levels in real-time, leading to more in-range blood sugars, fewer episodes of dangerously low blood sugar, and improved quality of life. Despite these benefits, CGM is not widely used in primary care settings, where most people receive their diabetes care. The investigators aim to make CGM more accessible and equitably prescribed in primary care practices. The study team will support primary care to increase CGM use with a program called SPARK-CGM (Supporting Primary Care Adoption, Resources, and Knowledge for CGM) across a large network of primary care clinics at Montefiore Medical Center. This program will provide primary care providers (PCPs) with education, tools, and support to incorporate CGM into their routine care for people with diabetes. Investigators plan to test SPARK-CGM to evaluate whether it increases CGM prescriptions who are eligible to receive this technology.",[30],[682,683,684,685],"Implementation","HbA1c","Multi-component Implementation","Continuous glucose monitoring","2026-06-22",{"date":688,"type":43},"2026-06-23",{"date":690,"type":43},"2026-05-01",{"date":692,"type":22},"2028-05",{"name":694,"class":50},"Montefiore Medical Center"]